Moderna's COVID-19 vaccine generated a "strong immune response" among children between the ages of 6 and 11, the company has announced.
Moderna revealed the interim results from a trial consisting of 4,753 participants between the ages of 6 and 11, and it said the vaccine was well-tolerated and generated a strong immune response, CNN reports. "The majority of adverse events were mild or moderate in severity," the company said. In the trial, two doses were given to children 28 days apart. The children received smaller doses than adults.
This comes as a Food and Drug Administration advisory board is set to meet this week to consider whether to authorize Pfizer's COVID-19 vaccine for young children. Pfizer recently said the vaccine is over 90 percent effective in kids between the ages of 5 and 11, and Dr. Anthony Fauci, President Biden's chief medical adviser, said the vaccine is likely to become available in this age group in November.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Meanwhile, both Modern and Pfizer are set to expand the size of clinical trials for their vaccine in young children as a "precautionary measure designed to detect rare side effects," The New York Times reports. Moderna said Monday it will submit its data to the FDA "in the near term."
-
The Icelandic women’s strike 50 years onIn The Spotlight The nation is ‘still no paradise’ for women, say campaigners
-
Mall World: why are people dreaming about a shopping centre?Under The Radar Thousands of strangers are dreaming about the same thing and no one sure why
-
Why scientists are attempting nuclear fusionThe Explainer Harnessing the reaction that powers the stars could offer a potentially unlimited source of carbon-free energy, and the race is hotting up
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
Why are autism rates increasing?The Explainer Medical experts condemn Trump administration’s claim that paracetamol during pregnancy is linked to rising rates of neurodevelopmental disorder in US and UK
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Cytomegalovirus can cause permanent birth defectsThe Explainer The virus can show no symptoms in adults
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
